Shared on10 Aug 25Fair value Increased 6.28%
Ascendis Pharma's consensus price target has been raised to $250.41, driven by strong commercial momentum for Yorvipath, positive pipeline developments—particularly in rare diseases—and compelling interim COACH trial data in achondroplasia, reinforcing analyst confidence in both near-term execution and long-term upside. Analyst Commentary Bullish analysts highlight strong commercial momentum and uptake for Yorvipath in hypoparathyroidism.
Shared on23 Apr 25Fair value Increased 0.0092%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 2.26%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 3.84%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 1.91%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 0.15%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.095%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Decreased 8.61%
AnalystConsensusTarget has decreased revenue growth from 72.3% to 61.0%, decreased profit margin from 36.6% to 31.4%, increased future PE multiple from 24.2x to 33.1x and decreased shares outstanding growth rate from 0.1% to 0.0%.